Back to Peptides
Gonadorelin
Hormone Regulation & Endocrine SupportGonadorelin is a synthetic gonadotropin-releasing hormone (GnRH) used for diagnostic and therapeutic purposes in reproductive and endocrine medicine. It stimulates the anterior pituitary to release LH and FSH and is used in fertility restoration, hormone replacement, and hypothalamic amenorrhea treatment.
Reconstitute
2 mL BAC + 2mg vial
10 mcg/unit
Daily Range
0.05–0.2 mg Intravenous (IV)
Single dose (diagnostic) or pulsatile dosing (therapeutic)
Standard Dose
0.1 mg
Cycle
4–8 weeks
then reassess
GonadorelinGnRH agonistpituitary testfertilityLH FSH stimulation
Dosing & Reconstitution Guide
Typical clinical research doses are 50–100 μg per injection. Gonadorelin is only approved for use in select diagnostic procedures.
Standard / Gradual Approach
2mg VialstandardPhaseDoseVolume
Weeks 1–2 (Initiation)50 mcg5 units (0.05 mL)
Weeks 3–4 (Titration)100 mcg10 units (0.10 mL)
Weeks 5–8 (Maintenance)100–150 mcg10–15 units (0.10–0.15 mL)
Standard / Gradual Approach
2mg VialadvancedPhaseDoseVolume
Days 1–7 (Burst)200 mcg20 units (0.20 mL)
Days 8–14 (Taper)100 mcg10 units (0.10 mL)
Week 3+ (Optional Maintenance)100 mcg 2–3×/wk10 units (0.10 mL)
Protocol Summary
Intravenous (IV): Single dose (diagnostic) or pulsatile dosing (therapeutic) · Dose range 0.05–0.2 mg with gradual titration
Cycle Length: 4–8 weeks typical; reassess before extending
Frequency & Cycling
IV
For diagnostic use: 0.1 mg IV as a single bolus. For therapeutic use: administered every 90–120 min in pulsatile infusion pumps over 7–14 days.
🧪 Quick Start
Vial Size
2 mg
BAC Water
2 mL
Concentration
1 mcg/unit
Starting Dose
50 mcg (5 units (0.05 mL))
Maintenance Dose
100–150 mcg (10–15 units (0.10–0.15 mL))
Potential Benefits & Use Cases
Gonadorelin is not approved for therapeutic use in the U.S. outside of diagnostic testing.
Supports endogenous testosterone production by stimulating LH release (human trial)
Maintains testicular volume and function during exogenous testosterone therapy (human trial)
Promotes spermatogenesis in hypogonadotropic hypogonadism — 90% reach qualified spermatogenesis within 5–18 months with pulsatile regimens (human trial)
Achieves spermatogenesis ~6 months faster than cyclical gonadotropin therapy (human trial)
Clinical data Strong preclinical Limited data
Mechanism of Action
→Acts as a GnRH receptor agonist on the anterior pituitary
→Induces secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH)
→Requires pulsatile administration to mimic physiological GnRH signaling
→Used in evaluating pituitary response and stimulating gonadal steroid production
Lifestyle & Optimization
timing
Consistent injection schedule to support hormonal rhythms.
diet
Balanced nutrition. Avoid excessive alcohol.
exercise
Resistance training.
sleep
Adequate sleep (7–9 hours) supports hormonal rhythms. Stress management.
Peptide Research & Preclinical Studies
Evidence-Based Research Findings
Side Effects & Safety
Common Side Effects
• Transient headache or flushing shortly after injection
🧮 Dose Calculator
Concentration
10.0
mcg/unit
Draw Volume
50
units (0.500 mL)
For a 500 mcg dose, draw 50 units on a U-100 insulin syringe
🧬
Bioavailability & Absorption
SubQ Injection
Low due to enzymatic degradation; typically not used subcutaneously
Oral Administration
Very poor; not viable orally
Half-Life
2–4 minutes
Degradation
Rapid degradation by plasma proteases and renal clearance
Tissue Specificity
Targets anterior pituitary GnRH receptors
⚗️
Peptide Details
Molecular Weight
1182
Formula
C55H75N17O13
Sequence
Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2
⚖️
Legal Status & Regulatory
RegionStatus
FDAApproved
EUApproved
AustraliaApproved
CanadaApproved
Storage Instructions
Lyophilized (Powder)
store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles
Reconstituted (Mixed)
Refrigerate at 2–8 °C (35.6–46.4 °F); use within 4 weeks and avoid freeze–thaw